Alector, Inc. ( ALEC ) NASDAQ Global Select

Cena: 1.51 ( 0.67% )

Aktualizacja 07-03 22:00
NASDAQ Global Select
Branża: Biotechnology
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Biotechnology
Zatrudnienie: 241
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 70%
Ilość akcji: 95 005 904
Debiut giełdowy: 2019-02-07
WWW: https://www.alector.com
CEO: Dr. Arnon Rosenthal Ph.D.
Adres: 131 Oyster Point Boulevard
Siedziba: 94080 South San Francisco
ISIN: US0144421072
Opis firmy:

Alection, Inc., firma biofarmaceutyczna stadium klinicznego, opracowuje terapie leczenia chorób neurodegeneracji. Jego produkty obejmują AL001, humanizowane rekombinowane przeciwciało monoklonalne, które jest w badaniu klinicznym fazy III w leczeniu demencji czołowo -skroniowej, choroby Alzheimera, Parkinsona i amiotroficznego stwardnienia bocznego; i AL101, który jest w badaniu klinicznym fazy I w leczeniu chorób neurodegeneracyjnych, w tym chorób Alzheimera i Parkinsona. Firma oferuje również Al002, kandydata na produkt, który jest w badaniu klinicznym fazy II w leczeniu choroby Alzheimera; i AL003, który jest w badaniu klinicznym fazy I w leczeniu choroby Alzheimera. Ponadto jego produkty w stadium rozwoju obejmują AL044, który jest skierowany do MS4A4A, gen ryzyka choroby Alzheimera. Altor, Inc. ma umowę o współpracy z Adimab, LLC w sprawie badań i rozwoju przeciwciał; oraz strategiczna umowa o współpracy z GlaxoSmithKline PLC w celu opracowania i komercjalizacji przeciwciał monoklonalnych, takich jak AL001 i AL101 w leczeniu chorób neurodegeneracyjnych. Firma została założona w 2013 roku i ma siedzibę w South San Francisco w Kalifornii.

Wskaźniki finansowe
Kapitalizacja (USD) 150 988 826
Aktywa: 516 023 000
Cena: 1.51
Wskaźnik Altman Z-Score: -2.2
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -1.2
Ilość akcji w obrocie: 70%
Średni wolumen: 905 162
Ilość akcji 99 992 600
Wskaźniki finansowe
Przychody TTM 61 508 000
Zobowiązania: 397 090 000
Przedział 52 tyg.: 0.87 - 6.78
Piotroski F-Score: 1
Słaby (niska jakość finansowa)
EPS: -1.3
P/E branży: 26.1
Beta: 0.657
Raport okresowy: 2025-08-05
WWW: https://www.alector.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Dr. Gary Romano M.D., Ph.D. Chief Medical Officer 752 171 1962
Dr. Marc Grasso M.D. Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer 728 714 1974
Dr. Saraswati Kenkare-Mitra Ph.D. President and Head of Research & Development 1 293 402 1968
Dr. Arnon Rosenthal Ph.D. Co-Founder, Chief Executive Officer & Director 1 064 236 1956
Ms. Danielle Pasqualone J.D., Ph.D. General Counsel 0 0
Ms. Virginia DeJesus-Rueff M.B.A. Chief of Staff & Head of Strategy 0 0
Ms. Katie Hogan Senior Director of Corporate Communication & Investor Relations 0 0
Ms. Kristina Cutter M.P.H. Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer 0 0
Mr. Peter Heutink Ph.D. Chief Scientific Officer 0 0
Ms. Clare Hunt M.B.A. Chief People Officer 0 0
Wiadomości dla Alector, Inc.
Tytuł Treść Źródło Aktualizacja Link
Alector Reports First Quarter 2025 Financial Results and Provides Business Update Topline data from pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN on track for Q4 2025 Completed enrollment in PROGRESS-AD Phase 2 clinical trial of AL101 in early Alzheimer's disease Continuing to pursue Alector Brain Carrier programs, including the company's anti-amyloid beta antibody and its GCase enzyme replacement therapy Extending runway into the second half of 2027, with $354.6 million in cash, cash equivalents, and investments SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today reported first quarter 2025 financial results and recent portfolio and business updates. globenewswire.com 2025-05-08 20:05:00 Czytaj oryginał (ang.)
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: Bank of America Securities Health Care Conference (Las Vegas, Nevada) Tuesday, May 13, 2025, at 2:20 p.m. globenewswire.com 2025-05-06 12:00:00 Czytaj oryginał (ang.)
Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer's Disease --76-week trial is evaluating the safety and efficacy of a progranulin-elevating candidate in slowing disease progression-- --Enrollment completed ahead of schedule-- SOUTH SAN FRANCISCO, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the completion of enrollment in PROGRESS-AD, a 76-week Phase 2 clinical trial evaluating the safety and efficacy of AL101/GSK4527226 in slowing disease progression in individuals with early Alzheimer's disease (AD). globenewswire.com 2025-04-17 12:00:00 Czytaj oryginał (ang.)
Alector Provides Executive Leadership Update --Giacomo Salvadore, M.D., appointed Chief Medical Officer-- --Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role-- globenewswire.com 2025-03-28 18:05:00 Czytaj oryginał (ang.)
Alector, Inc. (ALEC) Q4 2024 Earnings Call Transcript Alector, Inc. (NASDAQ:ALEC ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Katie Hogan - Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal - Co-Founder and Chief Executive Officer Gary Romano - Chief Medical Officer Sara Kenkare-Mitra - President and Head, Research and Development Marc Grasso - Chief Financial Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald Alec Stranahan - Bank of America Securities Thomas Shrader - BTIG Yaron Werber - TD Cowen Sarah Schram - William Blair Sam Lee - Mizuho Securities Operator Good afternoon, ladies and gentlemen, and welcome to Alector Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com 2025-02-27 03:09:22 Czytaj oryginał (ang.)
Alector (ALEC) Reports Q4 Loss, Tops Revenue Estimates Alector (ALEC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.49 per share a year ago. zacks.com 2025-02-26 20:55:25 Czytaj oryginał (ang.)
Alector Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025 Anticipate completing enrollment in the PROGRESS-AD Phase 2 clinical trial of AL101/GSK 4527226 in participants with early Alzheimer's disease by mid-2025 Applying Alector Brain Carrier to advance therapeutic candidates , including those targeting amyloid beta and replacing GCase $413.4 million in cash, cash equivalents and investments provide runway through 2026 Management to host conference call and webcast today at 4:30 p.m. ET/1:30 p.m. globenewswire.com 2025-02-26 18:05:00 Czytaj oryginał (ang.)
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2025-02-25 10:00:00 Czytaj oryginał (ang.)
Alector to Host Fourth Quarter and Full-Year 2024 Earnings Conference Call SOUTH SAN FRANCISCO, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced it will host a conference call and webcast on Wednesday, February 26, 2025, at 4:30 p.m. globenewswire.com 2025-02-19 18:05:00 Czytaj oryginał (ang.)
Alector Reports on Recent Progress and Outlines Strategic Priorities for 2025 Continue to advance preclinical and research pipeline, including key programs selectively combined with Alector Brain Carrier, enhancing the company's commitment to developing genetically-validated therapies for neurodegeneration globenewswire.com 2025-01-13 10:00:00 Czytaj oryginał (ang.)
Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts Bank of America Securities has downgraded Alector, Inc.  ALEC, citing the failure of its AL002 program. benzinga.com 2024-12-04 16:20:42 Czytaj oryginał (ang.)
ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal. zacks.com 2024-11-27 12:46:20 Czytaj oryginał (ang.)
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce On Monday, Alector, Inc.  ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). benzinga.com 2024-11-26 12:29:05 Czytaj oryginał (ang.)
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer's Disease and Provides Business Update SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer's clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer's fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels. As previously reported, MRI changes resembling amyloid-related imaging abnormalities (ARIA) and infusion-related reactions were observed in INVOKE-2. The instances of ARIA were primarily seen in participants treated with AL002. globenewswire.com 2024-11-25 18:05:00 Czytaj oryginał (ang.)
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $50 million. globenewswire.com 2024-11-14 18:05:00 Czytaj oryginał (ang.)
Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago. zacks.com 2024-11-06 20:50:19 Czytaj oryginał (ang.)
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer's disease (AD), on track for 2024 globenewswire.com 2024-11-06 18:05:00 Czytaj oryginał (ang.)
Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach. businesswire.com 2024-10-23 21:28:00 Czytaj oryginał (ang.)
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2024-08-29 11:00:00 Czytaj oryginał (ang.)
Alector, Inc. (ALEC) Q2 2024 Earnings Call Transcript Alector, Inc. (NASDAQ:ALEC ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Katie Hogan – Senior Director-Corporate Communications and Investor Relations Arnon Rosenthal – Co-Founder and Chief Executive Officer Sara Kenkare-Mitra – President and Head-Research and Development Gary Romano – Chief Medical Officer Marc Grasso – Chief Financial Officer Conference Call Participants Michael Reid – Morgan Stanley Carter Gould – Barclays Tom Shrader – BTIG Sarah Schram – William Blair & Company Ananda Ghosh – H.C. Wainwright & Company Graig Suvannavejh – Mizuho Securities Corinne Jenkins – Goldman Sachs Operator Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call. seekingalpha.com 2024-08-09 03:53:05 Czytaj oryginał (ang.)
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates Alector (ALEC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to earnings of $0.02 per share a year ago. zacks.com 2024-08-07 23:15:20 Czytaj oryginał (ang.)
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer's disease (AD) on track for Q4 2024 globenewswire.com 2024-08-07 20:05:00 Czytaj oryginał (ang.)
Alector to Host Mid-Year Earnings Conference Call Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT globenewswire.com 2024-07-31 20:05:00 Czytaj oryginał (ang.)
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®) --INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer's disease (AD)-- --Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD-- globenewswire.com 2024-07-28 12:05:00 Czytaj oryginał (ang.)
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024 SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced presentations related to the Company's TREM2 and progranulin programs at the upcoming Alzheimer's Association International Conference® 2024 (AAIC®) being held online and in Philadelphia, Pennsylvania from July 28 – August 1, 2024. globenewswire.com 2024-07-23 11:00:00 Czytaj oryginał (ang.)
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation globenewswire.com 2024-06-10 11:00:00 Czytaj oryginał (ang.)
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2024-05-09 11:00:00 Czytaj oryginał (ang.)
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates Alector (ALEC) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.55 per share a year ago. zacks.com 2024-05-08 23:26:18 Czytaj oryginał (ang.)
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2024-04-25 15:05:56 Czytaj oryginał (ang.)
Alector to Participate in Upcoming Healthcare Conferences SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences: globenewswire.com 2024-02-28 09:00:00 Czytaj oryginał (ang.)